Combination Therapy of Bcl-2/X L dual Inhibitor AZD0466 with Acalabrutinib to Overcome Therapeutic Resistance in Aggressive R/R Mantle Cell Lymphoma

被引：1

作者：

Li, Yijing ^{[1
]}

Liu, Yang ^{[1
]}

Che, Yuxuan ^{[1
]}

McIntosh, Joseph ^{[1
]}

Jordan, Alexa A. ^{[1
]}

Leeming, Angela ^{[1
]}

Andersen, Courtney L. ^{[2
]}

Cidado, Justin ^{[2
]}

Jin, Jingling ^{[1
]}

Jiang, Vivian Changying ^{[1
]}

Wang, Michael ^{[1
,3
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA

[2] AstraZeneca, Oncol R&D, Waltham, MA USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-151609

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1867

引用

页码：1867 / +

页数：4

共 36 条

[1] Dual Targeting Bcl-2 By Venetoclax and Mcl-1 By AZD5991 to Overcome Therapeutic Resistance in Aggressive R/R Mantle Cell Lymphoma
Li, Yijing
Liu, Yang
Che, Yuxuan
Jordan, Alexa A.
McIntosh, Joseph
Leeming, Angela
Andersen, Courtney L.
Cidado, Justin
Jin, Jingling
Jiang, Vivian Changying
Wang, Michael
BLOOD, 2021, 138
[2] Evaluation of a novel dual BCL-2/XL inhibitor (AZD0466) in acute leukemia
Kampa-Schittenhelm, K.
Froehlich, R.
Wieken, M.
Schittenhelm, M.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 84 - 84
[3] Design and optimization of a dendrimer-conjugated dual Bcl-2/Bcl-xL inhibitor, AZD0466, with improved therapeutic index
Ashford, Marianne B.
Balachander, Srividya B.
Graham, Lorraine
Grant, Iain
Gibbons, Francis D.
Hill, Kathryn J.
Harmer, Alexander R.
Gales, Sonya
Redmond, Sean
Kelly, Brian
McCoull, William
Wen, Shenghua
Wild, Martin
Gangl, Eric
Owen, David J.
Davies, Barry R.
CANCER RESEARCH, 2020, 80 (16)
[4] Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy
Claire M. Patterson
Srividya B. Balachander
Iain Grant
Petar Pop-Damkov
Brian Kelly
William McCoull
Jeremy Parker
Michael Giannis
Kathryn J. Hill
Francis D. Gibbons
Edward J. Hennessy
Paul Kemmitt
Alexander R. Harmer
Sonya Gales
Stuart Purbrick
Sean Redmond
Matthew Skinner
Lorraine Graham
J. Paul Secrist
Alwin G. Schuller
Shenghua Wen
Ammar Adam
Corinne Reimer
Justin Cidado
Martin Wild
Eric Gangl
Stephen E. Fawell
Jamal Saeh
Barry R. Davies
David J. Owen
Marianne B. Ashford
Communications Biology, 4
[5] Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy
Patterson, Claire M.
Balachander, Srividya B.
Grant, Iain
Pop-Damkov, Petar
Kelly, Brian
McCoull, William
Parker, Jeremy
Giannis, Michael
Hill, Kathryn J.
Gibbons, Francis D.
Hennessy, Edward J.
Kemmitt, Paul
Harmer, Alexander R.
Gales, Sonya
Purbrick, Stuart
Redmond, Sean
Skinner, Matthew
Graham, Lorraine
Secrist, J. Paul
Schuller, Alwin G.
Wen, Shenghua
Adam, Ammar
Reimer, Corinne
Cidado, Justin
Wild, Martin
Gangl, Eric
Fawell, Stephen E.
Saeh, Jamal
Davies, Barry R.
Owen, David J.
Ashford, Marianne B.
COMMUNICATIONS BIOLOGY, 2021, 4 (01)
[6] AZD0466, a dual BCL-2/XL targeting nanomedicine, is active in small cell lung cancer models
Andersen, Courtney L.
Fabbri, Giulia
Jenkins, David
Cader, Zumla
Sharma, Shringi
Tabatabai, Areya
Balachander, Srividya
Roebuck, Jordan
Galvin, Melanie
Simpson, Kathryn
Dive, Caroline
Ahnert, Jordi Rodon
Saeh, Jamal
CANCER RESEARCH, 2023, 83 (07)
[7] AZD4320 Is a Novel and Potent BCL-2/XL Dual Inhibitor in Targeting Aggressive Mantle Cell Lymphoma
Li, Yijing
Liu, Yang
McIntosh, Joseph
Jordan, Alexa A.
Leeming, Angela
Andersen, Courtney L.
Cidado, Justin
Jiang, Vivian Changying
Wang, Michael
BLOOD, 2020, 136
[8] AZD0466, a nanomedicine of a potent dual Bcl-2/Bcl-xL inhibitor, exhibits anti-tumor activity in a range of hematological and solid tumor models
Balachander, Srividya B.
Tabatabai, Areya
Wen, Shenghua
Gibbons, Francis D.
Fabbri, Giulia
Zhang, Guangnong Sunny
Cidado, Justin
Graham, Lorraine
Ashford, Marianne
Davies, Barry
CANCER RESEARCH, 2020, 80 (16)
[9] Dual targeting of PI3K and BCL-2 overcomes ibrutinib resistance in aggressive mantle cell lymphoma
Ye, Haige
Huang, Shengjian
Liu, Yang
Chen, Zhihong
Wang, Michael
Jiang, Vivian Changying
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2022, 26 (10) : 3068 - 3073
[10] PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma
Brown, Fiona
Zhang, Yang
Hinterschied, Claire
Prouty, Alexander
Sloan, Shelby
Helmig-Mason, JoBeth
Chung, Ji Hyun
Vaddi, Kris
Chen-Kiang, Selina
Di Liberto, Maurizio
Alinari, Lapo
Scherle, Peggy
Lapalombella, Rosa
Paik, Jihye
Baiocchi, Robert A.
BLOOD, 2019, 134

← 1 2 3 4 →